China joins with Philips for biomarker/Dx tests research:
This article was originally published in Clinica
China's Institute of Health Sciences (IHS) and Royal Philips Electronics signed a memorandum of understanding on August 29 to establish a joint molecular medicine research laboratory. The lab, which will be located at the IHS in Shanghai, will focus on biomarker discovery and the development of next-generation in vitro diagnostic tests, with the aim of developing new solutions for the early diagnosis of disease and for monitoring the effectiveness of subsequent treatment. The IHS is part of the Shanghai Institutes for Biological Sciences (SIBS).
You may also be interested in...
MeMed has received CE Marking for its diagnostic test MeMed BV and point-of-need platform MeMed Key, which uses the human immune system to distinguish between bacterial and viral infections to prevent antibiotic overuse.
The latest global vaccines summit has seen the launch of a new mechanism designed to spur the development of new coronavirus vaccines and ensure they are made available, particularly in low- and middle-income countries.
Progress for two US-based companies in the race to develop a COVID-19 vaccine.